TCT 2017: Elixir reveals new drug-eluting stent

229
Dynamx

Elixir Medical unveiled for the first time its novel stent technology—Dynamx—at the 2017 Transcatheter Cardiovascular Therapeutics (TCT) meeting (29 October–2 November, Denver, USA). A press release reports that Dynamx is a bioadaptive drug-eluting stent that has a 71 microns thin cobalt-chromium platform with a thin, biodegradable polymer coating that releases novolimus.

Novolimus is an antiproliferative and anti-inflammatory that has been designed to allow the vessel to resume arterial pulsatile motion and the Glagovian phenomenon of adaptive remodelling. Adaptive segments in the stent are held intact by the thin biodegradable polymer coating designed to absorb in six months allowing the adaptive segments to uncage the stent and restore the natural pulsatile motion and adaptive remodelling of the artery.

According to the press release, Dynamx demonstrated significantly improved conformability, and reduced torsional and longitudinal stresses compared to current drug-eluting stents—thereby reducing geometric distortion of arteries and the potential for stent fractures and clinical events.

Elixir unveiled Dynamx at a evening symposium on the Monday of the TCT meeting and the symposium was attended by cardiologists from around the world and industry professionals. The first clinical experience with DynamX was also presented Stefan Verheye (Antwerp, Belgium). He comments: “The acute performance of DynamX matched the best in class drug-eluting stent. I am very excited about the potential of DynamX leading PCI to the next frontier.”

In addition to launching a new genre of bioadaptive drug eluting stents with Dynamx, Elixir also continues to make advances with its bioresorbable scaffold programmes—DESolve CX and DESolve NXT. The press release states that DESolve’s ability to degrade in six months and nearly completely resorb in one year, while demonstrating positive adaptive remodelling at six month follow-up have all been affirmations of their respective proprietary technologies and the promising future of the category.

“Elixir is committed to lead the industry to a new and exciting era with its bioadaptive DynamX drug-eluting stent. Elixir is executing on a two-pronged strategy with BRS and BA-DES to develop innovative, adaptive remodelling technologies designed to restore the normal function of arteries,” says Motasim Sirhan, CEO of Elixir Medical.

(Visited 113 times, 1 visits today)

LEAVE A REPLY

Please enter your comment!
Please enter your name here